

8359

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

227/LG/SE/OCT/2019/GBSL

25th October 2019

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

To
The Manager
National Stock Exchange Of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code : 509079

Symbol : GUFICBIO

Dear Sir,

Sub: Submission of Report on Reconciliation of Share Capital Audit for the quarter ended September 30, 2019.

With reference to above, we submit herewith Report on Reconciliation of Share Capital Audit for the quarter ended September 30, 2019 for reconciliation of share capital in electronic mode and physical mode, received from M/s. Gajanan D. Athavale, Practicing Company Secretary, Mumbai.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Gufic Biosciences Limited



Ami N. Shah
Company Secretary & Compliance Officer
Mem No. A39579

Encl: A/a



01, Pushpak, Bhaskar Colony, Naupada, Thane (West), Maharashtra State - 400 602.

E: gajanan@aathavale.com U: www.aathavale.com M: 91- 9870567711 S: live:gajanan.athavale

To,
The Board of Directors,
Gufic Biosciences Limited.
Mumbai

Reconciliation of Share Capital Audit of M/s. Gufic Biosciences Limited

BSE Scrip Code: 509079

NSE Scrip Code: GUFICBIO

Company Identification Number: L24100MH1984PLC033519

Sir/Madam,

Based on reports/certificates of the Company appointed Registrars and Transfer Agents; M/s. Link Intime India Pvt. Ltd., which was further supported by the management's written representation dated 25 October 2019; in terms of Regulation 55A of the SEBI (Depositories and Participants) Regulations, 1996 read with the Circular D&CC/FITTC/CIR-16/2002 dated 31 December 2002 as amended by the Circular No. SEBI/MRD/ Policy/Cir-13/2004 dated March 3, 2004 and circular CIR/MRD/DP/30/2010 dated 06 September 2010, *presently in force and to the extent repealed by regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018*; I hereby report on the reconciliation of share capital of Gufic Biosciences Limited for the quarter ended 30 September 2019 as follows in a prescribed format:

Sr. No.	Particulars	
1.	For the quarter ended	30 September 2019
2.	ISIN	INE742B01025
3.	Face Value	Re.1/-
4.	Name of the Company	Gufic Biosciences Limited
5.	Registered Office Address	Shop 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai – 400 069
6.	Correspondence Address (Corporate Office)	SM house, 11 Sahakar Road, Vile Parle (East), Mumbai – 400057
7.	Telephone & Fax	Tele: 022 – 67261000 Fax: 022 – 67261067
8.	Email ID	mgr_legal@guficbio.com
9.	Names of the Stock Exchanges where the company's securities are listed	1. Bombay Stock Exchange Limited (BSE) 2. National Stock Exchange of India Limited (NSE)





01, Pushpak, Bhaskar Colony, Naupada, Thane (West), Maharashtra State - 400 602.

E: gajanan@aathavale.com U: www.aathavale.com M: 91- 9870567711 S: live:gajanan.athavale

10.	Issued Capital	Number of Equity Shares		issued capital %				
		77,830,000		100				
11.	Listed Capital (Exchange-wise) (as per company records)	77,830,000 (similar listing on both exchanges viz: BSE & NSE)		100				
12.	Held in dematerialised form in NSDL	7,25,45,025		93.21				
13.	Held in dematerialised form in CDSL	51,61,479		6.63				
14.	Physical	1,23,496		0.16				
15.	Total No. of Shares (12 + 13 + 14)	7,78,30,000		100.00				
16.	Reasons for difference if any, between (10 & 11), (10 & 15), (11 & 15)	--- N.A. ---						
17.	Certifying the details of changes in share capital during the quarter under consideration as per table below:							
	Particulars (Rights, Bonus, Issue, Amalgamation, Conversion, Capital Forfeiture, any other (to specify)	(Rights, Preferential ESOPs, Buyback, Reduction, any other)	No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whet her intima ted to CDSL	Whet her intima ted to NSDL	In principle approval pending for SE (Specify names)
----- N.A.-----								
18.	Register of Members is updated (Yes / No) If not, updated upto which date	Yes (as confirmed by RTA vide its letter dated 05 October 2019.)						
19.	Reference of previous quarter with regards to excess dematerialised shares, if any.	N.A.						
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	N.A.						
21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending, beyond 21 days with the reasons for delay.							
	Total no. of demat requests		No. of requests		No. of shares		Reasons for delay	
	Confirmed after 21 days		As per reports of RTA, during the quarter no request for DEMAT,					
	Pending for more than 21 days		transfer, transmission, etc., were received.					



GAJANAN



01, Pushpak, Bhaskar Colony, Naupada, Thane (West), Maharashtra State - 400 602.

E: gajanan@aathavale.com U: www.aathavale.com M: 91- 9870567711 S: live:gajanan.athavale

22.	Name, Telephone & Fax No. of the Compliance Officer of the Company	Ami Shah, Company Secretary & Compliance Officer Tel: 022 – 67261000 Fax: 022 – 67261067
23.	Name, Address, Tel. & Fax No., Regn. no. of the Auditor	Gajanan D. Athavale, Company Secretaries 01, Pushpak, Bhaskar Colony, Naupada, Thane (West), Maharashtra State – 400 602 Membership No. F-9177 CoP No. 10121
24.	Appointment of common agency for share registry work, if yes (name & address)	LINK INTIME INDIA PVT. LTD. C-101, 247 Park, L.B.S. Marg, Vikhroli (W), Mumbai - 400 083. Tel No.: (022) 4918 6270 Fax (022) 49186060 Email: mt.helpdesk@linkintime.co.in
25.	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)	N.A.

For Gajanan D. Athavale
Company Secretaries



Gajanan D. Athavale
Proprietor

Membership No. FCS-9177

Certificate of Practice: 10121

UDIN F009177A000167830

Place: Thane

Date: 25 October 2019